"use strict";(self.webpackChunkBenStockTracker=self.webpackChunkBenStockTracker||[]).push([[5676],{5676:e=>{e.exports=JSON.parse('{"3dff04b4-26ba-35f3-a3ab-2bfd99099f7d":{"uuid":"3dff04b4-26ba-35f3-a3ab-2bfd99099f7d","title":"Gilead Sciences (GILD) Stock Moves -0.72%: What You Should Know","publisher":"Zacks","link":"https://finance.yahoo.com/news/gilead-sciences-gild-stock-moves-214509843.html","providerPublishTime":1654897509,"type":"STORY"},"8c44dced-5d64-321f-96e0-7114bbc1475a":{"uuid":"8c44dced-5d64-321f-96e0-7114bbc1475a","title":"Gilead Sciences is a Finalist for the PinkNews Awards in the Business Equality Category","publisher":"News Direct","link":"https://finance.yahoo.com/news/gilead-sciences-finalist-pinknews-awards-132508822.html","providerPublishTime":1654867508,"type":"STORY"},"98ad418a-f03c-3117-b54f-2df94b343cfe":{"uuid":"98ad418a-f03c-3117-b54f-2df94b343cfe","title":"Read This Before Considering Gilead Sciences, Inc. (NASDAQ:GILD) For Its Upcoming US$0.73 Dividend","publisher":"Simply Wall St.","link":"https://finance.yahoo.com/news/read-considering-gilead-sciences-inc-103233726.html","providerPublishTime":1654857153,"type":"STORY"},"0486275e-fc39-309d-96cd-d701f2df854a":{"uuid":"0486275e-fc39-309d-96cd-d701f2df854a","title":"Gilead Joining the Global Access to Oncology Medicines Coalition","publisher":"News Direct","link":"https://finance.yahoo.com/news/gilead-joining-global-access-oncology-135513986.html","providerPublishTime":1654696513,"type":"STORY"},"2ffd8110-5900-3f86-a586-b700fa4d574d":{"uuid":"2ffd8110-5900-3f86-a586-b700fa4d574d","title":"7 Oversold Stocks to Buy Right Now","publisher":"InvestorPlace","link":"https://finance.yahoo.com/news/7-oversold-stocks-buy-now-110007965.html","providerPublishTime":1654686007,"type":"STORY"},"3c71d4ae-de8f-3cbc-b86c-a5028f82d5d3":{"uuid":"3c71d4ae-de8f-3cbc-b86c-a5028f82d5d3","title":"Final Data From Phase 3 ASCENT Study Demonstrates Trodelvy Extends Overall Survival Over Chemotherapy in Second-Line Metastatic TNBC","publisher":"Business Wire","link":"https://finance.yahoo.com/news/final-data-phase-3-ascent-130000245.html","providerPublishTime":1654520400,"type":"STORY"},"3bc394a5-02c6-3fb8-962d-ebadad96ccd8":{"uuid":"3bc394a5-02c6-3fb8-962d-ebadad96ccd8","title":"UPDATE 1-Gilead drug modestly delays breast cancer progression in late-stage trial","publisher":"Reuters","link":"https://finance.yahoo.com/news/1-gilead-drug-modestly-delays-214039634.html","providerPublishTime":1654378839,"type":"STORY"},"04d15a71-12cb-33df-92a0-db090cd99cd9":{"uuid":"04d15a71-12cb-33df-92a0-db090cd99cd9","title":"Tecartus\xae Car T-cell Therapy Demonstrates Strong Overall Survival Rates and Continued Durable Responses in Long-Term Follow-Up of Two Pivotal Studies Including Longest Ever Follow-Up of a CAR T-cell Therapy in Mantle Cell Lymphoma","publisher":"Business Wire","link":"https://finance.yahoo.com/news/tecartus-car-t-cell-therapy-200000654.html","providerPublishTime":1654372800,"type":"STORY"}}')}}]);